Hologic to Complete Third Wave Purchase Today | GenomeWeb
NEW YORK (GenomeWeb News) – Hologic said that it would complete its $580 million acquisition of Third Wave Technologies after the close of business today.
 
The Bedford, Mass.-based medical imaging and diagnostics firm said that as of midnight last night, Third Wave shareholders had tendered 47,968,050 shares of the firm, representing 95.8 percent of Third Wave’s outstanding stock. Hologic paid $11.25 per share for Third Wave’s stock, which will cease trading on the Nasdaq after today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.